316 related articles for article (PubMed ID: 31677933)
1. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose.
Skoy E; Eukel H; Werremeyer A; Strand M; Frenzel O; Steig J
J Am Pharm Assoc (2003); 2020; 60(1):117-121. PubMed ID: 31677933
[TBL] [Abstract][Full Text] [Related]
2. Program evaluation of the Opioid and Naloxone Education (ONE Rx) program using the RE-AIM model.
Strand MA; Eukel H; Frenzel O; Skoy E; Steig J; Werremeyer A
Res Social Adm Pharm; 2020 Sep; 16(9):1248-1254. PubMed ID: 31812501
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a Program to Screen Patients in Community Pharmacies for Opioid Misuse and Accidental Overdose.
Skoy E; Frenzel O; Eukel H; Lothspeich E; Steig J; Strand M; Werremeyer A
Prev Chronic Dis; 2022 Jul; 19():E41. PubMed ID: 35834737
[TBL] [Abstract][Full Text] [Related]
4. Patient acceptance of naloxone resulting from targeted intervention from community pharmacists to prevent opioid misuse and accidental overdose.
Skoy E; Werremeyer A; Steig J; Eukel H; Frenzel O; Strand M
Subst Abus; 2021; 42(4):672-677. PubMed ID: 33044896
[No Abstract] [Full Text] [Related]
5. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
6. Impact of a statewide community pharmacy approach to opioid harm reduction.
Sexton SM; Marciniak MW; Gatton O; Shelton P
J Am Pharm Assoc (2003); 2023; 63(1):389-395.e1. PubMed ID: 36369073
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the opioid and naloxone education (ONE) program: Program evaluation using the RE-AIM model four years later.
Strand MA; Frenzel O
Res Social Adm Pharm; 2024 Jul; 20(7):648-653. PubMed ID: 38627152
[TBL] [Abstract][Full Text] [Related]
8. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
[TBL] [Abstract][Full Text] [Related]
9. Patient, family members and community pharmacists' views of a proposed overdose prevention intervention delivered in community pharmacies for patients prescribed high-strength opioids for chronic non-cancer pain: An explorative intervention development study.
Mercer F; Parkes T; Foster R; Steven D; McAuley A; Baldacchino A; Steele W; Schofield J; Matheson C
Drug Alcohol Rev; 2023 Mar; 42(3):517-526. PubMed ID: 36165733
[TBL] [Abstract][Full Text] [Related]
10. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
[TBL] [Abstract][Full Text] [Related]
11. Pharmacy on-site overdose protocols and prevention of overdose.
Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
[TBL] [Abstract][Full Text] [Related]
12. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
[TBL] [Abstract][Full Text] [Related]
13. Preparing student pharmacists to identify opioid misuse, prevent overdose and prescribe naloxone.
Skoy E; Eukel H; Frenzel J; Werremeyer A
Curr Pharm Teach Learn; 2019 May; 11(5):522-527. PubMed ID: 31171255
[TBL] [Abstract][Full Text] [Related]
14. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
[TBL] [Abstract][Full Text] [Related]
15. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
Bailey AM; Wermeling DP
Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
[TBL] [Abstract][Full Text] [Related]
16. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.
Binswanger IA; Rinehart D; Mueller SR; Narwaney KJ; Stowell M; Wagner N; Xu S; Hanratty R; Blum J; McVaney K; Glanz JM
J Gen Intern Med; 2022 Aug; 37(11):2624-2633. PubMed ID: 35132556
[TBL] [Abstract][Full Text] [Related]
17. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
Melaragni F; Levy C; Pedrazzi J; Andersen M
J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
[TBL] [Abstract][Full Text] [Related]
18. Piloting an opioid callback program in community pharmacies.
Hernandez SE; Gilson AM; Gassman M; Ford JH
J Am Pharm Assoc (2003); 2023; 63(6):1796-1802. PubMed ID: 37574197
[TBL] [Abstract][Full Text] [Related]
19. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
[TBL] [Abstract][Full Text] [Related]
20. Pharmacy-based statewide naloxone distribution: A novel "top-down, bottom-up" approach.
Morton KJ; Harrand B; Floyd CC; Schaefer C; Acosta J; Logan BC; Clark K
J Am Pharm Assoc (2003); 2017; 57(2S):S99-S106.e5. PubMed ID: 28292508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
